US Bioservices to dispense Alnylam's Onpattro injection
US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen has been chosen by Alnylam Pharmaceuticals to be one of the specialty pharmacies to dispense Onpattro (patisiran) lipid complex injection.
Onpattro was recently approved by the Food and Drug Administration for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or hATTR, in adults and is a RNA interference therapy targeting transthyretin.
US Bioservices will provide comprehensive specialty pharmacy services to patients who are being treated with Onpattro.
“US Bioservices is proud to partner with Alnylam to facilitate access to treatment and provide integrated, personalized solutions to patients with this devastating disease,” Bioservices president of United States Kelly Ratliff said, in a press statement. “Over the past two decades, we have innovated to keep pace with the rapidly changing medical and scientific landscape, and we welcome the opportunity to support hATTR amyloidosis patients with polyneuropathy who are prescribed Onpattro.”
Onpattro is administered via intravenous infusion by a healthcare professional once every three weeks, and will be available through the specialty pharmacy channel at both infusion clinics and in the patient’s home, if covered under the patient’s insurance plan, according to the company.
Patients prescribed Onpattro who receive services from US Bioservices will have access to its national team of in-home nurses in the convenience of a patient’s home. The company’s telephonic nurses will be available to provide 24/7 clinical support to patients on therapy.
Onpattro was recently approved by the Food and Drug Administration for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or hATTR, in adults and is a RNA interference therapy targeting transthyretin.
US Bioservices will provide comprehensive specialty pharmacy services to patients who are being treated with Onpattro.
“US Bioservices is proud to partner with Alnylam to facilitate access to treatment and provide integrated, personalized solutions to patients with this devastating disease,” Bioservices president of United States Kelly Ratliff said, in a press statement. “Over the past two decades, we have innovated to keep pace with the rapidly changing medical and scientific landscape, and we welcome the opportunity to support hATTR amyloidosis patients with polyneuropathy who are prescribed Onpattro.”
Onpattro is administered via intravenous infusion by a healthcare professional once every three weeks, and will be available through the specialty pharmacy channel at both infusion clinics and in the patient’s home, if covered under the patient’s insurance plan, according to the company.
Patients prescribed Onpattro who receive services from US Bioservices will have access to its national team of in-home nurses in the convenience of a patient’s home. The company’s telephonic nurses will be available to provide 24/7 clinical support to patients on therapy.